Long-term therapy of venous thromboembolism in cancer patients

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 9, 2006, Pages 903-910

  Streiff, Michael B ^a,b  

^a Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ^*  (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Cancer; Deep vein thrombosis; Low molecular weight heparin; Pulmonary embolism; Venous thromboembolism; Vitamin K antagonist

Indexed keywords

ANTIVITAMIN K; DABIGATRAN; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; TINZAPARIN; WARFARIN;

ADVANCED CANCER; ARTICLE; BLEEDING; CANCER PATIENT; CLINICAL TRIAL; COMORBIDITY; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; INCIDENCE; INFERIOR CAVA VEIN; LONG TERM CARE; MORBIDITY; MORTALITY; PATHOGENESIS; RECURRENCE RISK; RECURRENT DISEASE; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT OUTCOME; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

EID: 33750070021     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0075     Document Type: Article

References (51)

1. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-815.
2. Deitcher SR. Cancer and thrombosis: mechanisms and treatment. J Thromb Thrombolysis 2003;16:21-31.
3. Peuscher FW. Thrombosis and bleeding in cancer patients. Neth J Med 1981;24:23-35.
4. Dvorak HF. Abnormalities of hemostasis in malignant disease. In: Colman RW, Hirsh J, Marder VJ, et al., eds. Hemostasis and Thrombosis. Philadelphia: J.B. Lippincott, 1994:1238-1254.
5. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-1850.
6. Shen VS, Pollak EW. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J 1980;73:841-843.
7. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001;102:V215-V224.
8. Nash GF, Walsh DC, Kakkar AK. The role of the coagulation system in tumour angiogenesis. Lancet Oncol 2001;2:608-613.
9. Gale AJ, Gordon SG. Update on tumor cell procoagulant factors. Acta Haematol 2001;106:25-32.
10. Bergqvist D. Venous thromboembolism and cancer: prevention of VTE. Thromb Res 2001;102:V209-V213.
11. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404-407.
12. Pritchard KI, Paterson AH, Paul NA, et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996;14:2731-2737.
13. Holm T, Singnomklao T, Rutqvist LE, Cedermark B. Adjuvant pre-operative radiotherapy in patients with rectal carcinoma. Adverse effects during long term follow-up of two randomized trials. Cancer 1996;78:968-976.
14. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126 (3 suppl):204S-233S.
15. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:631-639.
16. Bona RD, Hickey AD, Wallace DM. Efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 1997;78:137-140.
17. Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000;84:805-810.
18. Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-3083.
19. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488.
20. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001;345:165-169.
21. Moore FD Jr, Osteen RT, Karp DD, et al. Anticoagulants, venous thromboembolism, and the cancer patient. Arch Surg 1981;116:405-407.
22. Cohen JR, Tenenbaum N, Citron M. Greenfield filter as primary therapy for deep venous thrombosis and/or pulmonary embolism in patients with cancer. Surgery 1991;109:12-15.
23. Streiff MB. Vena caval filters: a review for intensive care specialists. J Intensive Care Med 2003;18:59-79.
24. Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004;164:1653-1661.
25. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005;112:416-422.
26. White RH, Zhou H, Kim J, Romano PS. A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism. Arch Intern Med 2000;160:2033-2041.
27. Stein PD, Alnas M, Skaf E, et al. Outcome and complications of retrievable inferior vena cava filters. Am J Cardiol 2004;94:1090-1093.
28. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):188S-203S.
29. Fareed J, Leong WL, Hoppensteadt DA, et al. Generic low-molecular-weight heparins: some practical considerations. Semin Thromb Hemost 2004;30:703-713.
30. Wells PS, Anderson DR, Rodger MA, et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med 2005;165:733-738.
31. Pini M, Aiello S, Manotti C, et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994;72:191-197.
32. Veiga F, Escriba A, Maluenda MP, et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost 2000;84:559-564.
33. Das SK, Cohen AT, Edmondson RA, et al. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 1996;20:521-526.
34. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:1729-1735.
35. Deitcher SR, Kessler CM, Merli O, et al. Secondary prevention of venous thromboembolic events in patients with active malignancy: a randomized study of enoxaparin sodium alone versus initial enoxaparin sodium followed by warfarin for a 180 day period [abstract]. Proc Am Soc Clin Oncol 2003;22:761. Abstract 3060.
36. Hull RD, Pineo GF, Mah AF, Brant RF. A randomized trial evaluating long-term low molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium [abstract]. Blood 2002;100:148a. Abstract.
37. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.
38. Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126 (3 suppl):401S-428S.
39. Segal JB, Bolger DT, Jenckes MW, et al. Outpatient therapy with low-molecular weight heparin for the treatment of venous thromboembolism: a review of efficacy, safety, and costs. Am J Med 2003;115:298-308.
40. Aujesky D, Smith KJ, Cornuz J, Roberts MS. Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism. Thromb Haemost 2005;93:592-599.
41. White RH. The epidemiology of venous thromboemholism. Circulation 2003;107(23 suppl 1):14-18.
42. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006;166:729-736.
43. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003;21:3665-3675.
44. Brandjes DP, Bullet HR, Heijboer H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997;349:759-762.
45. Prandoni P, Lensing AW, Prins MH, et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 2004;141:249-256.
46. Luk C, Wells PS, Anderson D, Kovacs MJ. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med 2001;111:270-273.
47. Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001;134:191-202.
48. Levin JM, Schiff D, Loeffler JS, et al. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 1993;43:1111-1114.
49. Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs 2006;15:843-855.
50. Spinler SA. New concepts in heparin-induced thrombocytopenia: diagnosis and management. J Thromb Thrombolysis 2006;21:17-21.
51. Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost 2005;3:1843-1853.